NCT07158905 AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)
| NCT ID | NCT07158905 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Institute for Molecular Medicine |
| Condition | Alzheimer Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2026-06-23 |
| Primary Completion | 2029-06-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 48 participants in total. It began in 2026-06-23 with a primary completion date of 2029-06-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple-dose-escalation study evaluating the safety, tolerability, and immunogenicity of AV-1980R, an investigational vaccine targeting pathological tau, in participants with preclinical Alzheimer's disease. Up to 48 cognitively unimpaired adults aged 65 to 80 years with biomarker evidence of preclinical Alzheimer's disease will be enrolled into three ascending-dose cohorts.
Eligibility Criteria
Inclusion Criteria: Male or postmenopausal or surgically sterile female, 65 to 80 years of age, inclusive. Cognitively unimpaired participant with preclinical Alzheimer's disease who meets all of the following: Clinical Dementia Rating global score of 0 at Screening. Mini-Mental State Examination score ≥26, with education adjustment at Screening. Plasma p-tau217/Aβ42 ratio ≥0.00738 measured using Lumipulse (Fujirebio). A prior positive result obtained within 12 months before Screening may be accepted but must be confirmed by the central laboratory. Sight and hearing, including use of a hearing aid, sufficient to comply with study procedures. Stable concomitant medications. Participants receiving fluctuating medication or treatment may be considered if the underlying condition is controlled. Signed informed consent before any study-related procedure. Ability, in the Investigator's opinion, to understand the study and comply with protocol requirements. Exclusion Criteria: Screening MRI showing any of the following: More than one noncortical lacunar infarct greater than 1.5 cm. Any territorial infarct greater than 1.5 cm. Combined microbleeds and areas of leptomeningeal hemosiderosis greater than 5, or disseminated leptomeningeal hemosiderosis. Any other significant cerebral abnormality, including ARIA-E. Contraindication to MRI, including non-MRI-safe implanted metallic devices or clinically significant claustrophobia. Serious illness requiring systemic treatment or hospitalization within 4 weeks before study entry. Clinically relevant cardiovascular, respiratory, gastrointestinal, endocrine, immunologic, hematologic, systemic disease, or major surgery that could interfere with participation or follow-up. Insulin-dependent diabetes. Clinically relevant cardiac arrhythmia, palpitation, conduction abnormality, prolonged QT interval, or bundle branch block. Pre-existing autoimmune disease. C-SSRS score of 3 or higher. History of seizure disorder, except permitted stable use of certain antiepileptic medications for chronic pain. Any medical, psychological, or social condition that could interfere with participation, compliance, or participant safety. Participation in another investigational drug study or use of an investigational drug within 30 days or 5 half-lives, whichever is longer, before dosing. Prior tau or amyloid-beta immunotherapy within 1 year before Screening. Use of specified immunomodulatory or growth-stimulating treatments within 30 days before study entry. Chronic use for more than 3 months of warfarin, other coumarin derivatives, anticoagulants, or an antiplatelet agent such as clopidogrel. Parenteral immunoglobulin preparations, blood products, or plasma derivatives. History of severe local or systemic vaccination reactions or significant allergic reactions. Clinically significant laboratory abnormalities at Screening, including ALT or AST greater than 1.5 times the upper limit of normal. Positive testing for HIV-1 or HIV-2, hepatitis B surface antigen, or hepatitis C.
Contact & Investigator
Michael Agadjanyan, PhD
PRINCIPAL INVESTIGATOR
Institute MM
Frequently Asked Questions
Who can join the NCT07158905 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, up to 80 Years, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07158905 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07158905 currently recruiting?
Yes, NCT07158905 is actively recruiting participants. Contact the research team at rkniazev@immed.org for enrollment information.
Where is the NCT07158905 trial being conducted?
This trial is being conducted at Boca Raton, United States, Miami Lakes, United States, Stuart, United States, Tampa, United States and 2 additional locations.
Who is sponsoring the NCT07158905 clinical trial?
NCT07158905 is sponsored by Institute for Molecular Medicine. The principal investigator is Michael Agadjanyan, PhD at Institute MM. The trial plans to enroll 48 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.